Skip to main content

Diabetes

  • FDA approves Novo Nordisk’s Xultophy 100/3.6 for Type 2 diabetes
    SILVER SPRING, Md. — Novo Nordisk announced Monday that the Food and Drug Administration had approved its Xultophy 100/3.6 (insulin degludec 100 units/ML and liraglutide 3.6 mg/mL). The drug is indicated to improve glycemic control in adults with Type 2 diabetes inadequately controlled on less than 50 units of basal insulin daily or less than or equal to 1.8 mg of liraglutide daily. 
     

  • Sanofi’s Soliqua 100/33 for Type 2 diabetes gets FDA nod
    SILVER SPRING, Md. — The Food and Drug Administration has approved Sanofi’s Soliqua 100/33 (insulin glargine 100 units/mL and lixisenatide 33mcg/mL), the company announced Monday. The drug is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide. 
     

  • FDA approves Ascensia’s app-enabled blood glucose monitoring system
    PARSIPPANY, N.J. — Ascensia Diabetes Care announced Monday that the Food and Drug Administration had approved the company’s Contour Next One blood glucose monitoring system. The blood glucose smart meter can connect to mobile devices via Bluetooth to facilitate easier management within the Contour Diabetes app. 
     

  • Omnis Health launches new gestational diabetes care kit

    NASHVILLE — Earlier this year, Omnis Health created a dedicated diabetes-management solution for some 375,000 women diagnosed with gestational diabetes who are extremely passionate, both about managing their condition and the health of their newborns. It’s certainly a niche category, but the retailer who provides a direct solution to gestational diabetes may capture that family’s entire health spend moving forward.

  • ADA recommends diabetes patients get a move on — every 30 minutes

    Retailers may soon want to add fitness guides and office-friendly exercise equipment to their diabetes sets. The American Diabetes Association last month released new guidance suggesting physical movement improves blood-sugar management for people who have sedentary jobs, and in people who are overweight, obese and who have difficulty maintaining blood sugars in a healthy range.

    (To view the full Diabetes Report, click here.)

  • Free screenings help break barriers to care

    With the advent of complimentary health screenings available through a growing number of retail health fairs — such as CVS Health, Walmart and Sam’s Club and ShopRite, to name a few — more and more consumers are learning for the first time that they may be diabetic or prediabetic from their neighborhood pharmacist as opposed to their primary care doctors.

    (To view the full Diabetes Report, click here.)

  • Apps, tech differentiate new meters

    More and more, meter manufacturers today are differentiating their offerings not by the traditional micrometers of blood necessary for a viable glucose reading or the value inherent in the cost of test strips, but in the accompanying adherence app or other technologies that will help diabetes patients better navigate their disease states.

    (To view the full Diabetes Report, click here.)

  • Mobile app helps patients, cos. increase adherence

    Diabetics are most adherent around meal times, especially during breakfast and toward the beginning of the week, according to a review of Medisafe’s more than 160,000 diabetes patients who utilize its adherence tool in an effort to better manage the condition.

    (To view the full Diabetes Report, click here.)

X
This ad will auto-close in 10 seconds